Parmax Pharma Ltd

Other Announcement

Parmax Pharma Other Announcement

Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.

Annual General Meeting

Parmax Pharma Annual General Meeting

Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.

Capital Structure Change

Parmax Pharma Capital Structure Change

Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.

Value

₹8.32 Cr

Capital Structure Change

Parmax Pharma Capital Structure Change

Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.

Financial Results

Parmax Pharma Q1 FY27 Results: Turns Profitable, Net Profit ₹2.2 Cr

Parmax Pharma Ltd reported revenue from operations of ₹8.2 Cr (+331.6% YoY) and net profit of ₹2.2 Cr for Q1 FY27.

Key figure

Net profit ₹2.2 Cr

Financial Results

Parmax Pharma Q4 FY26 Results: Net Loss of ₹0.6 Cr, Loss Narrows

Parmax Pharma Ltd reported revenue from operations of ₹3.3 Cr (-31.2% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.

Key figure

Net loss ₹0.6 Cr